Brendon Binneman

797 total citations
17 papers, 592 citations indexed

About

Brendon Binneman is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Brendon Binneman has authored 17 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 6 papers in Physiology and 5 papers in Pharmacology. Recurrent topics in Brendon Binneman's work include Alzheimer's disease research and treatments (6 papers), Schizophrenia research and treatment (6 papers) and Treatment of Major Depression (4 papers). Brendon Binneman is often cited by papers focused on Alzheimer's disease research and treatments (6 papers), Schizophrenia research and treatment (6 papers) and Treatment of Major Depression (4 papers). Brendon Binneman collaborates with scholars based in United States, Sweden and United Kingdom. Brendon Binneman's co-authors include Ruolun Qiu, Sheela Kolluri, Douglas E. Feltner, Catherine Hughes, Mrigendra Das, W. Soni, Veena Kumari, Tonmoy Sharma, Carol Cronenberger and Martin M. Bednar and has published in prestigious journals such as American Journal of Psychiatry, Schizophrenia Bulletin and Schizophrenia Research.

In The Last Decade

Brendon Binneman

17 papers receiving 561 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brendon Binneman United States 11 236 142 130 129 120 17 592
Mariana Pedrini Brazil 16 336 1.4× 122 0.9× 334 2.6× 94 0.7× 64 0.5× 29 783
Dachun Chen China 20 493 2.1× 96 0.7× 312 2.4× 131 1.0× 79 0.7× 58 1.0k
Haruhiko Sugino Japan 8 318 1.3× 62 0.4× 165 1.3× 82 0.6× 216 1.8× 8 710
Yoshiteru Takekita Japan 16 321 1.4× 46 0.3× 157 1.2× 49 0.4× 239 2.0× 48 845
Rosa Catalán Spain 16 283 1.2× 38 0.3× 182 1.4× 147 1.1× 258 2.1× 29 866
Jason D. Kilts United States 16 158 0.7× 95 0.7× 126 1.0× 247 1.9× 74 0.6× 31 1.0k
Annarita Barone Italy 14 189 0.8× 48 0.3× 151 1.2× 46 0.4× 30 0.3× 39 536
Rodrigo Labarca United States 13 249 1.1× 80 0.6× 152 1.2× 143 1.1× 56 0.5× 18 896
Habibeh Yekehtaz Iran 13 267 1.1× 75 0.5× 257 2.0× 71 0.6× 152 1.3× 15 831
Christopher M. Marano United States 12 264 1.1× 127 0.9× 132 1.0× 54 0.4× 89 0.7× 12 687

Countries citing papers authored by Brendon Binneman

Since Specialization
Citations

This map shows the geographic impact of Brendon Binneman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendon Binneman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendon Binneman more than expected).

Fields of papers citing papers by Brendon Binneman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendon Binneman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendon Binneman. The network helps show where Brendon Binneman may publish in the future.

Co-authorship network of co-authors of Brendon Binneman

This figure shows the co-authorship network connecting the top 25 collaborators of Brendon Binneman. A scholar is included among the top collaborators of Brendon Binneman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendon Binneman. Brendon Binneman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Fullerton, Terence, Brendon Binneman, William David, et al.. (2018). A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimer s Research & Therapy. 10(1). 38–38. 27 indexed citations
2.
Syed, Sana, et al.. (2018). Evaluation of the use of the Scale for the Assessment and Rating of Ataxia (SARA) in healthy volunteers and patients with schizophrenia. Journal of the Neurological Sciences. 391. 40–44. 1 indexed citations
3.
4.
Landen, Jaren W., Niels Andreasen, Carol Cronenberger, et al.. (2017). Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study. Alzheimer s & Dementia Translational Research & Clinical Interventions. 3(3). 393–401. 49 indexed citations
5.
Landen, Jaren W., Sharon Cohen, Clare B. Billing, et al.. (2017). Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. Alzheimer s & Dementia Translational Research & Clinical Interventions. 3(3). 339–347. 50 indexed citations
6.
Fullerton, Terence, Brendon Binneman, William David, et al.. (2016). P1‐047: A Phase 2 Clinical Trial of PF‐05212377 (SAM‐760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil. Alzheimer s & Dementia. 12(7S_Part_8). 1 indexed citations
7.
Miyoshi, Izuru, Yoko Fujimoto, Qinying Zhao, et al.. (2013). Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. International Journal of Clinical Pharmacology and Therapeutics. 51(12). 911–923. 20 indexed citations
8.
Landen, Jaren W., Niels Andreasen, Carol Cronenberger, et al.. (2012). P4‐209: Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF‐04360365) in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_19). 3 indexed citations
9.
Cronenberger, Carol, Kathryn Wright, Kelly R. Bales, et al.. (2012). P1‐012: Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_3). 18 indexed citations
10.
Binneman, Brendon, et al.. (2008). A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression. American Journal of Psychiatry. 165(5). 617–620. 185 indexed citations
11.
Fleming, K A, Steven G. Potkin, Brendon Binneman, et al.. (2007). P.3.c.073 Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. European Neuropsychopharmacology. 17. S466–S467. 13 indexed citations
12.
Breier, Alan, Larry Alphs, & Brendon Binneman. (2007). Commentary: Wayne Fenton's Impact on Industry. Schizophrenia Bulletin. 33(5). 1154–1155. 1 indexed citations
13.
Neumeister, Alexander, Richard E. Carson, Shannan Henry, et al.. (2006). Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects. Journal of Clinical Psychopharmacology. 26(6). 595–599. 10 indexed citations
14.
Das, Mrigendra, Veena Kumari, W. Soni, et al.. (2004). Neurological Soft Signs and Their Relationship to Cognitive and Clinical Efficacy of Atypical Antipsychotics in Schizophrenia. Schizophrenia Bulletin. 30(2). 241–253. 22 indexed citations
15.
Hughes, Catherine, Veena Kumari, W. Soni, et al.. (2002). Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophrenia Research. 59(2-3). 137–146. 172 indexed citations
16.
Mehrotra, Ravi, W. Soni, Xavier Chitnis, et al.. (2000). Neurological soft signs in chronic schizophrenia: Clinical, cognitive and structural correlates. Schizophrenia Research. 41(1). 262–262. 1 indexed citations
17.
Soni, W., et al.. (2000). Change in negative symptoms with risperidone predicts improved quality of life in schizophrenia. Schizophrenia Research. 41(1). 199–200. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariana Pedrini Breakdown of academic impact, for papers by Dachun Chen Breakdown of academic impact, for papers by Haruhiko Sugino Breakdown of academic impact, for papers by Yoshiteru Takekita Breakdown of academic impact, for papers by Rosa Catalán Breakdown of academic impact, for papers by Jason D. Kilts Breakdown of academic impact, for papers by Annarita Barone Breakdown of academic impact, for papers by Rodrigo Labarca Breakdown of academic impact, for papers by Habibeh Yekehtaz Breakdown of academic impact, for papers by Christopher M. Marano
Rankless by CCL
2026